Innate Pharma

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Innate Pharma was founded in 1999 by Hervé Brailly, a French clinician, and Frédéric Dalloyau, a French engineer. In November 2003, Innate Pharma was publicly listed at Euronext Paris, followed by a Nasdaq listing in May 2014. Headquartered in Marseilles, France, Innate Pharma operates an oncology research and development center, with various research and development collaborations.

At Innate, we drive drug discovery and development in order to create first-in-class drugs and treatments and delivery therapies that are tailored to patient needs and that leverage their distinct features to produce better outcomes and enhanced patient quality of life.

Innate Pharma has embraced a holistic vision of medical care and healing for our patients with the goal of creating innovative treatments that are personalised, predictive, and more effective than any existing therapies.

Innate Pharma

Share

Contacts

Follow Us

Innate Pharma

Share

Contacts

Follow Us